Assessment of the relationship between the ambulatory electrocardiography-based micro T-wave alternans and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy

Introduction

Hypertrophic cardiomyopathy (HCM) is defined as a heart muscle disorder characterized by left ventricular (LV) and/or right ventricular hypertrophy, and it is an important cause of death in patients of all ages, especially in the young (1). Although most of these patients remain asymptomatic or experience only paroxysmal manifestations (2), others die suddenly due to ventricular tachycardia (VT) or fibrillation (3). In such cases, the implantable cardioverter-defibrillator (ICD) is the first-line treatment for HCM. Identification of patients who are at high risk of ventricular arrhythmias (VA) or sudden cardiac death (SCD) is of paramount importance when selecting patients for ICD implantation. Inadequate evaluation in this regard may cause a lack of adequate attention to patients who really need an ICD, or cause unnecessary ICD insertion in patients who will never benefit from it. The European Society of Cardiology (ESC) Guidelines recommend the use of a risk stratification model when deciding which patient will be treated with an ICD. The predicted 5-year risk of SCD (the HCM Risk-SCD) is an HCM SCD risk model that assesses risk stratification and helps to identify high-risk patients who require an ICD (HCM Risk-SCD of >6%) (4).

Objective: Micro T-wave alternans (MTWA) has been associated with poor arrhythmic prognosis in various cardiac disorders. The aim of this study was to assess the relationship between the presence of MTWA and the predicted 5-year risk of sudden cardiac death (HCM Risk-SCD) among patients with hypertrophic cardiomyopathy (HCM).

Methods: A total of 117 consecutive HCM patients were included in this prospective observational study. Patients were divided into two groups, according to the presence [MTWA (+) group (n=44)] or absence [MTWA (−) group (n=73)] of MTWA on ambulatory (Holter) electrocardiography.

Results: The rate of high-risk patients (HCM Risk-ECG >6%), the requirement for cardiopulmonary resuscitation, and implanted cardioverter defibrillator therapy, the percentage of some clinical, echocardiographic, and Holter findings were all statistically higher in the MTWA (+) group than in the MTWA (−) group (all p<0.05). Both in the univariate and multivariate analyses, T-wave alternans (+) and the New York Heart Association’s functional classification assigned that the HCM Risk-SCD is an independent predictor of high risk. The receiver operating characteristic curve analysis, the HCM Risk-SCD >4.9% was identified as an effective cutoff point in the MTWA (+) for HCM. The HCM Risk-SCD value of more than 4.9 yielded a sensitivity of 93.2% and a specificity of 84.5%.

Conclusion: The presence of the MTWA on ambulatory electrocardiogram seems to be significantly associated with increasing percentages of the predicted HCM Risk-SCD score in patients with HCM. The MTWA was determined as an independent high-risk indicator for HCM Risk-SCD.

Keywords: hypertrophic cardiomyopathy, ambulatory electrocardiography, sudden cardiac death, score
Relationship between MTWA and the HCM Risk-SCD in HCM

Özyılmaz and Püşüroğlu

Anatol J Cardiol 2018; 20: 165-73
DOI:10.14744/AnatolJCardiol.2018.15945

Methods

Patient population

This study included 117 consecutive patients with HCM who presented to the Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital and Bezmi-alem Vakf University, School of Medicine. Study data were obtained evaluating the patients from these two hospitals using the devices in a single hospital. This study was conducted as a prospective observational study between December 2012 and March 2016. The study was approved by the Ethics Committee in the Bezmi-alem Vakf University, School of Medicine. All patients signed informed consent forms. This study was conducted in compliance with the Declaration of Helsinki.

The study inclusion criteria were the following: Patients whose echocardiography (ECHO) revealed HCM, or HCM defined as a maximum LV wall thickness ≥15 mm in one or more LV myocardial segments with unexplained abnormal loading conditions (1); with lesser degrees of wall thickening; a family history, positive gene mutations, and electocardiogram (ECG) abnormalities; and apical hypertrophy assessed by cardiac magnetic resonance (CMR) imaging. The patients, especially those in whom Anderson-Fabry disease was suspected, were screened (35 patients), and none of them was positive. These evaluations identified adult patients (>17 years) with a high possibility of HCM for inclusion in the study.

In this study, we included only those patients who were evaluated for the ICD treatment for primary protection.

Exclusion criteria

We excluded patients with a prior history of ICD for secondary protection, or prior cardiac arrest and sustained VT, and we excluded from our analysis patients with prolonged uncontrolled hypertension, renal failure, a history of coronary artery disease, aortic valve stenosis, atrial fibrillation, previous permanent pacemaker implantation, metabolic storage disease, and other moderate-to-severe valve diseases.

Patients with a body mass index (BMI) over 30 kg/m² were also excluded. Competitive athletes, pediatric patients, and patients with a LV wall thickness ≥35 mm were not included. The final study population consisted of 117 patients.

Electrocardiography

A 12-lead surface ECG was obtained in all patients in the supine position. The ECG records were taken using a Nihon Koh-den-Cardiofax S instrument (ECG-1250 K, filter range 0.5 Hz to 150 Hz, AC filter 60 Hz, at a speed of 25 mm/s and an amplitude of 10 mm/mV; Nihon Kohden, Tokyo, Japan). We assessed the rhythm, speed, and presence or absence of a fragmented QRS on ECG.

Echocardiography

Upon hospital admission, a transthoracic echocardiography (ECHO) study was performed using a Vivid S5 system (General Electric Vivid S5; GE Vingmed Ultrasound AS, Horten, Norway) with a 1.7/3.4 MHz phased-array transducer. All ECHO parameters were measured offline, and an average of three cardiac cycles was used. The biplane Simpson method was used for the calculation of the LV ejection fraction (LVEF) (8). The LV wall thickness, LV end diastolic diameter (LVEDD), and LV end systolic diameter (LVESD) were measured in the parasternal long axis. The LV outflow tract obstruction gradient (LVOTG) was measured in the apical five chambers. In addition, the LV end diastolic volume, end systolic volume, left atrial (LA) diameter, LA volume, LA volume index (LAVI), and LV mass in grams were calculated from M-mode echocardiograms according to the formulas described by Devereux et al. (9). We calculated the LV mass and the LV mass index with CMR in patients with markedly asymmetric or apical hypertrophy. The LV mass was indexed to body surface area as the LV mass index (LVMI) in g/m². The mitral valve regurgitation and the relative wall thickness index (RWTI) were also evaluated.

Ambulatory ECG-based microvolt T-wave alternans

The Spectral and the MMA methods are two contemporary techniques used for risk stratification of arrhythmias by microvolt-level TWA. In this study, we used the MMA method for the evaluation of MTWA (7). Twelve-channel records of ambulatory Holter monitoring were used for the analyses during daily activity. Ambulatory ECG recordings (DMS 300-7 Holter Reader; DSM, Stateline, NV, USA) were obtained for 24 hours in all patients at the admission and follow-up. Evaluations of TWA were obtained during the admission. The TWA was reported at the predetermined times associated with cardiovascular stress, including the maximum heart rate and maximum ST segment deviation. Prior to an automatic analysis of the tapes with the Holter program (CardioScan 12.0DM software, DSM), the recordings were evaluated for rhythm anomalies, and the TWA value was measured at a maximum heart rate <120 beats/min. The MARS PC software was used to identify the possible TWA periods according to the MMA algorithm, which is a time-domain-based method that bifurcates the beat stream to generate
The study population was divided into two groups based on the admission MTWA: the first group (n=44) [MTWA (+)] and the second group (n=73) [MTWA (−)]. Qualitative variables were expressed as percentages (%), and quantitative variables as the mean ± standard deviation (SD). The normally distributed continuous variables were assessed using the Kolmogorov–Smirnov test. A comparison of the parametric values between the two groups was performed with a two-tailed Student’s t-test. Categorical variables were compared with the likelihood ratio (chi) 2 or Fisher’s exact test. Pearson’s correlation coefficient was used for correlation comparisons between groups. A p-value less than 0.05 was considered statistically significant. All statistical studies were carried out using the SPSS program (version 15.0, SPSS, Inc., Chicago, IL, USA).

**Study end-point and follow-up**

In this study, the mean follow-up period was 31.7±12.7 months. The patients’ medical histories, family history of SCD, syncope, and a questionnaire on lifestyle and risk factors were taken. Patients were regularly followed-up in an outpatient clinic at regular 3-month intervals. Any change in the patient’s clinical status was noted. Holter monitoring was performed at least once in all patients and at least twice in those with more than one risk factor for SCD. Holter monitoring was also performed when patients had any possible arrhythmic symptoms, including dizziness, palpitations, and syncope. The primary end-point for the study was mortality and sustained ventricular tachyarrhythmias requiring ICD interventions. The secondary end-point was the occurrence of major arrhythmic events. The follow-up for clinical end-points was performed by telephone interviews and a review of outpatient and inpatient medical records.

**Results**

**Baseline characteristics and micro T-wave alternans results**

The baseline and clinical characteristics of all patients are shown in Table 1. The mean age of the 117 patients was 46.6±15.2 years. Of those 117 patients, 71 (60.8%) were male. The functional capacity was New York Heart Association (NYHA) II in 53 and NYHA III in 25 patients. A total of 49% of the patients had HCM in their first-degree relatives. During the follow-up, 36% experienced presyncope, and 12% experienced syncope. A total of 39 patients were admitted to the hospital with heart failure (HF) symptoms. A total of 12 patients had paroxysmal atrial fibrillation (PAF), 24 had NSVT attacks, 14 patients needed CPR, ICD implantation was performed in 12 patients, and a two-chamber pacemaker was implanted in 1 patient. A total of 8 patients with ICD had appropriate shock, 6 patients underwent myectomy, and 1 patient underwent alcohol septal ablation. β-blockers were administered in 107, amiodarone in 4, calcium channel blockers in 5, and dysopropamid in 8 patients.

A comparison of the results between the MTWA (+) (n=44) and the MTWA (−) (n=73) groups is shown in Table 1. No statistically significant correlation was found in terms of age (years), gender, BMI (kg/m²), diabetes mellitus (%), HT (%), hyperlipidemia (%), syncope (%), LVEF (%), RWTI, the LVOTO gradient (mm Hg), and PAF (%), in the MTWA (−) and MTWA (+) groups (all p>0.05). The rate of family history (57%; 33%), presyncope (47%; 20%), HCM Risk-SCD (9.1±4.3; 3.6±2.3), HCM Risk-SCD (>6%) (88%; 8%), VT (43%; 8%), CPR (25%; 4%), ICD implantation (23%; 3%), shock (18%; 0%), and admittance with HF (48%; 16%) were higher in the MTWA (+) group than in the MTWA (−) group, and all results were statistically significant (all p<0.05). The LAAPD (mm) (43.2±4.4; 41.5±4.2), LAV (ml) (59.4±16.2; 48.8±14.2), LAVI
Table 1. Baseline and clinical characteristics of all patients

| Variabilities                      | All (n=117) | MTWA(+) (n=44) | MTWA(-) (n=73) | P       |
|-----------------------------------|-------------|----------------|----------------|---------|
| Age (years)                       | 46.6±15.2   | 43.8±14.4      | 48.3±15.4      | 0.120   |
| Gender                            |             |                |                |         |
| Male (%)                          | 71 (60.6%)  | 32 (72)        | 39 (53)        | 0.081   |
| Female (%)                        | 46 (39.4%)  | 12 (28)        | 34 (47)        |         |
| Body mass index (kg/m²)           | 26.7±3.5    | 26.4±3.2       | 26.9±3.6       | 0.478   |
| Diabetes mellitus (%)             |             |                |                |         |
| (+)                               | 7           | 3 (7)          | 4 (5)          | 1.000   |
| (-)                               | 110         | 41 (93)        | 69 (95)        |         |
| Hypertension (%)                  |             |                |                |         |
| (+)                               | 5           | 3 (7)          | 2 (3)          | 0.363   |
| (-)                               | 112         | 41 (93)        | 71 (97)        |         |
| Family history (%)                |             |                |                |         |
| (+)                               | 49          | 25 (57)        | 24 (33)        | 0.013   |
| (-)                               | 68          | 19 (43)        | 49 (67)        |         |
| HL (%)                            |             |                |                |         |
| (+)                               | 23          | 9 (20)         | 14 (19)        | 1.000   |
| (-)                               | 94          | 35 (80)        | 59 (81)        |         |
| Cigarettes (%)                    |             |                |                |         |
| (+)                               | 22          | 10 (23)        | 12 (16)        | 0.466   |
| (-)                               | 95          | 34 (77)        | 61 (84)        |         |
| Presyncope (%)                    |             |                |                |         |
| (+)                               | 36          | 21 (47)        | 15 (20)        | 0.003   |
| (-)                               | 81          | 23 (53)        | 58 (80)        |         |
| Syncope (%)                       |             |                |                |         |
| (+)                               | 12          | 8 (18)         | 4 (5)          | 0.055   |
| (-)                               | 105         | 36 (82)        | 69 (95)        |         |
| NYHA (%) class                    |             |                |                |         |
| I                                 | 39 (32)     | 8 (18)         | 31 (42)        |         |
| II                                | 53 (47)     | 18 (41)        | 35 (47)        | <0.001  |
| III                               | 25 (21)     | 17 (41)        | 8 (11)         |         |
| Beta blockers (%)                 |             |                |                |         |
| (+)                               | 107         | 41 (93)        | 66 (90)        | 0.741   |
| (-)                               | 10          | 3 (7)          | 7 (10)         |         |
| Amiodarone (%)                    |             |                |                |         |
| (+)                               | 4           | 3 (7)          | 1 (2)          | 0.149   |
| (-)                               | 113         | 41 (93)        | 72 (98)        |         |
| Dysopyramide (%)                  |             |                |                |         |
| (+)                               | 8           | 5 (11)         | 3 (4)          | 0.150   |
| (-)                               | 109         | 39 (89)        | 70 (96)        |         |
Table 1. Cont.

| Variabilities                                      | All (n=117) | MTWA(+) (n=44) | MTWA(-) (n=73) | P      |
|---------------------------------------------------|-------------|----------------|----------------|--------|
| Calcium channel blocker (%)                       |             |                |                |        |
| (+)                                               | 5           | 3 (7)          | 2 (3)          | 0.363  |
| (-)                                               | 112         | 41 (93)        | 71 (97)        |        |
| The HCM Risk-SCD (%)                              |             |                |                | <0.001 |
| (>6%) (%)                                          | 42          | 36 (82)        | 6 (8)          | <0.001 |
| (<6%) (%)                                          | 75          | 8 (18)         | 67 (92)        |        |
| LAAPD (mm)                                        | 42.1±4.3    | 43.2±4.4       | 41.5±4.2       | 0.042  |
| LAV (ml)                                          | 52.8±15.8   | 59.4±16.2      | 48.8±14.2      | <0.001 |
| LAVI (ml/m²)                                      | 29.6±8.9    | 32.7±9.7       | 27.8±7.8       | 0.004  |
| LV EF (%)                                         | 66.6±7.1    | 66.8±6.6       | 66.4±7.4       | 0.804  |
| IVST (mm)                                         | 21.8±4.4    | 23.9±4.9       | 20.6±3.7       | <0.001 |
| LVPWT (mm)                                        | 12.8±3.1    | 13.1±3.8       | 12.5±2.5       | 0.329  |
| LVM (g)                                           | 332.3±87.1  | 371.2±98.5     | 300.1±70.6     | <0.001 |
| LVMI (g/m²)                                       | 180.1±54.1  | 200.1±65.9     | 168.1±41.8     | 0.002  |
| RWTI                                              | 0.61±0.22   | 0.64±0.29      | 0.60±0.18      | 0.394  |
| LVOTOG (mm Hg)                                    | 25.7±29.8   | 30.8±32.8      | 22.7±27.7      | 0.162  |
| Paroxysmal atrial fibrillation (%)                |             |                |                |        |
| (+)                                               | 12          | 7 (16)         | 5 (7)          | 0.209  |
| (-)                                               | 105         | 38 (84)        | 67 (93)        |        |
| Ventricular tachycardia (%)                       |             |                |                |        |
| (+)                                               | 24          | 19 (43)        | 6 (8)          | <0.001 |
| (-)                                               | 91          | 25 (57)        | 66 (92)        |        |
| Cardiopulmonary resuscitation (%)                |             |                |                | <0.001 |
| (+)                                               | 14          | 11 (25)        | 3 (4)          |        |
| (-)                                               | 103         | 33 (75)        | 70 (96)        |        |
| ICD implantation (%)                              |             |                |                | <0.001 |
| (+)                                               | 12          | 10 (23)        | 2 (3)          |        |
| (-)                                               | 105         | 34 (77)        | 71 (97)        |        |
| Shock (%)                                         |             |                |                |        |
| Aproperate                                        | 8           | 8 (18)         | 0              | 0.001  |
| inappropriate                                      | 3           | 2 (4)          | 1 (1)          |        |
| Admitted with heart failure (%)                   |             |                |                | 0.001  |
| (+)                                               | 33          | 21 (48)        | 12 (16)        |        |
| (-)                                               | 84          | 23 (52)        | 61 (84)        |        |
| Sudden death/VT-VF (+), appropriate shock (+) group|             |                |                | <0.001 |
| (+)                                               | 29          | 22 (50)        | 7 (11)         |        |
| (-)                                               | 88          | 22 (50)        | 66 (89)        |        |

Values are the mean±standard deviation or number (%).

EF - ejection fraction, HCM - hypertrophic cardiomyopathy, HCM Risk-SCD - predicted 5-year risk of sudden cardiac death in HCM patients, ICD - implantable cardioverter defibrillator, IVST - interventricular septum thickness, LAAPD - left atrium anterior–posterior dimension, LAV - left atrium volume, LAVI - left atrium volume index, LVEDD - left ventricular end-diastolic dimension, LVE3D - left ventricular end-systolic dimension, LVM - left ventricular mass, LVMI - left ventricular mass index, LVPWT - left ventricular posterior wall thickness, LVOTO - left ventricular outflow tract obstruction, NYHA - New York Heart Association, RWTI - relative wall thickness index, SCD - sudden cardiac death.
(ml/m²) (32.7±9.7; 27.8±7.8), IVST (mm) (23.9±4.9; 20.6±3.7), and LVM (g) (371.2±98.5; 309.1±70.6), and LVMi (g/m²) (200.1±65.9; 168.1±41.8) were statistically significantly higher in the MTWA (+) group compared to the MTWA (-) group (all p<0.05).

Patients were divided into two groups: those who had experienced sudden death/VT-ventricular fibrillation (VF), appropriate shock (n=29, 24.7%), and those who did not (n=88, 75.3%). The HCM-SCD risk score was 10.0±5.3 in the group with VT-VF and appropriate shock. The HCM-SCD risk score was 4.3±2.4, p-value <0.001, in the non-group. The sudden death/VT-VF (+), appropriate shock (+) group (n=29, 24.7%), were higher in the MTWA (+) group than in the MTWA (-) group, and results were statistically significant (p<0.001) (Table 1).

Correlation between micro T-wave alternans and other parameters

A statistically significant correlation was established between the MTWA and the rate of family history (r=0.285; p=0.011), presyncope (r=0.285, p=0.002), syncope (r=0.203, p=0.028), the NYHA class (r=0.358, p<0.001), the HCM Risk-SCD (r=0.632, p<0.001), the HCM Risk-SCD (>6%) (r=0.759, p<0.001), the LAAPD (r=0.189, p=0.042), LAV (r=0.325, p<0.001), LAVi (r=0.267, p=0.004), LV EF (%) (r=0.023, p=0.804), IVST (mm) (r=0.346, p<0.001), LVPWT (mm) (r=0.092, p=0.329), LVM (g) (r=0.287, p=0.002), LVMi (g/m²) (r=0.346, p<0.001), RWTI (r=0.081, p=0.394), LVOTOG (mm Hg) (r=0.131, p=0.162), PAF (%) (r=0.138, p=0.138), Ventricular tachycardia (%) (r=0.411, p<0.001), CPR (%) (r=0.342, p<0.001), ICD implantation (%) (r=0.353, p<0.001), Admitted heart failure (%) (r=0.341, p<0.001), and Appropriate shock (%) (r=0.304, p=0.001).

There was no statistically significant correlation found between the MTWA and the other parameters (Table 2).

Results of the logistic regression analysis

Univariate (UVA) and multivariate analyses (MA) of the independent predictors of high risk for HCM Risk-SCD are shown in Table 3. Both in the UVA and MA, MTWA (+) [UVA: odds ratio (OR): 59.400, confidence interval (CI): 18.091–195.030, p<0.001; MA: OR: 79.741, CI: 13.685–464.687, p<0.001] and the NYHA (UVA: OR: 0.196, CI: 0.098–0.394, p<0.001; MA: OR: 0.300, CI: 0.096–0.941, p=0.039) shock (n=29, 24.7%), and those who did not (n=88, 75.3%). The HCM-SCD risk score was 10.0±5.3 in the group with VT-VF and appropriate shock. The HCM-SCD risk score was 4.3±2.4, p-value <0.001, in the non-group. The sudden death/VT-VF (+), appropriate shock (+) group (n=29, 24.7%), were higher in the MTWA (+) group than in the MTWA (-) group, and results were statistically significant (p<0.001) (Table 1).

Correlation between micro T-wave alternans and other parameters

A statistically significant correlation was established between the MTWA and the rate of family history (r=0.285; p=0.011), presyncope (r=0.285, p=0.002), syncope (r=0.203, p=0.028), the NYHA class (r=0.358, p<0.001), the HCM Risk-SCD (r=0.632, p<0.001), the HCM Risk-SCD (>6%) (r=0.759, p<0.001), the LAAPD (r=0.189, p=0.042), LAV (r=0.325, p<0.001), LAVi (r=0.267, p=0.004), IVST (mm) (r=0.346, p<0.001), LVM (g) (r=0.287, p=0.002), LVMi (g/m²) (r=0.346, p<0.001), percentage of VT (r=0.411, p=0.001), CPR (%) (r=0.342, p<0.001), and ICD implantation (%) (r=0.353, p<0.001), admittance for HF (r=0.341, p<0.001), and appropriate shock (r=0.304, p<0.001). There was no statistically significant correlation found between the MTWA and the other parameters (Table 2).
assigned that the HCM Risk-SCD is an independent predictor of high risk. In a ROC curve analysis, the HCM Risk-SCD >4.9 was identified as an effective cutoff point in the MTWA (+) for HCM (area under curve=0.932, 95% CI=0.887-0.978, p<0.001). A HCM Risk-SCD value of more than 4.9 yielded a sensitivity, specificity, positive, and negative predictive values of 93.2%, 84.5 %, 86%, and 89%, respectively (Fig. 2).

### Discussion

Ventricular malignant arrhythmias and SCD are well-known complications of HCM. VT/VF are the most common cause of SCD in patients with HCM. The ICD therapy is an important treatment option for preventing SCD and improving prognosis. However, ICD hardware may become seeded and lead to infective endocarditis and inappropriate ICD shocks. Moreover, self-perpetuating procedures such as requirement for subsequent generator changes are disadvantages of this treatment (11, 12). For these reasons, it is important to choose the patient who really needs the ICD treatment.

Recently, even if microvolt TWA seems like a promising test for the identification of sudden death in various heart diseases, data to support the use of TWA to withhold or delay the ICD implantation are yet insufficient. In addition, intracardiac repolarization alternans plays an important pathogenetic role in the formation of malignant arrhythmias in channelopathies. There is no previous study to show that the TWA analysis assesses the arrhythmic risk in patients with Brugada syndrome or long QT (13, 14). In the present study, we investigated whether the MTWA could be a potential predictor of cardiac events, focusing on arrhythmic events and the predicted HCM Risk-SCD in patients with HCM. The most important findings of this study are as follows: The number of patients with a predicted HCM Risk-SCD greater than 6% was significantly higher, and the percentage of VT and the necessity for CPR and ICD therapy and appropriate shock were significantly higher in the MTWA (+) group. Patients describing the NYHA class III HF symptoms and the incidence of hospitalization due to the general impairment caused by deficiency were significantly higher in the MTWA (+) group. There was a significant relationship between positive MTWA and IVST, LVM, LVMI, LAAPD, LAV, and LAVI. A positive MTWA and an increased level of NYHA functional classification were found to be independent high-risk predictors for the HCM Risk-SCD.

The MTWA is a non-invasive method for identifying patients at increased risk of SCD from VA (15, 16). On the other hand, the test’s alternative usefulness appears to be the detection of a group of patients with low risk for the development of malignant VA, because a negative test result strongly predicts freedom from VT-VF (17). This would help to separate these patients from those who are more likely to benefit from the ICD use. Otherwise, a significant proportion of these patients will never have access to these devices (18). The alternation of T-waves in patients with HCM may possibly be explained as a result of the following mechanisms. First, abnormal cell-to-cell conduction may contribute to the inhomogeneous action potential propagation and heterogeneous repolarization, which result in the alternans of T-wave in HCM. Second, fibrous tissue replacement of both RV and LV, an important characteristic of HCM, may delay cell-to-cell conduction and facilitate the development of re-entrant ventricular arrhythmias (19). Previous studies have shown that re-entry is the main mechanism responsible for ventricular arrhythmias causing sudden deaths (20). Third, myocardial ischemia may be one of the causes of the MTWA positivity. Myocardial ischemia due to microvascular dysfunction (MD) and supply-demand mismatches in coronary blood flow (21) occurring in HCM, is an important pathophysiologic component of the disease process, and leads...
to heterogeneous repolarization gradients between myocytes. The discordant alternans establish heterogeneous repolarization gradients, which are thought to be highly arrhythmogenic (22). Furthermore, MD promotes the LV myocardial scarring and remodeling (23) by acting as a facilitator for excessive myocardial fibrosis. Slower conduction, which may initiate a re-entry circuit, occurs as a result of all these pathological mechanisms, and beat-to-beat alternation in the amplitude or morphology of the ECG recording of the ST segment and T-wave. In the present study, IVST, LVM, and LVMI were significantly higher in patients with positive MTWA.

Microvascular dysfunction, which is thought to play a role in the pathological mechanism of the TWA formation, has been advanced as a predictor of a long-term outcome and HF death (23). In most patients, there is a lifelong process of progressive and adverse cardiac remodeling characterized by myocardial fibrosis and wall thinning (24, 25). In the early stages of this process, patients are often asymptomatic, and conventional non-invasive indices of cardiac performance are within the normal range. Progression to severe functional limitation with preserved LV systolic function NYHA III–IV is infrequent (3). In this study, a significant relationship was observed between an increasing functional classification and the TWA positivity. Admission to the hospital with HF symptoms was correlated with positive MTWA.

As is well known, the most feared complication of HCM is SCD, and it is often the initial clinical manifestation of the disease, occurring commonly in asymptomatic individuals. ICD is the best available therapy for patients with HCM who have survived SCD or who are at high risk of life-threatening ventricular arrhythmias (26). The NSVT, severe hypertrophy, unexplained syncope, a family history of SCD, and an abnormal blood pressure response to exercise (27) have been used in clinical practice for a long time; however, these approaches provide a very crude estimate of the relative risk of SCD, and they fail to account for the differences in the size of the effects of individual risk factors. The ESC Guidelines for HCM recommend a practical risk prediction model in line with the requirement absolute value for the risk of SCD (1). According to this model, the HCM Risk-SCD ≥6% is considered to be a high risk for SCD, and an ICD treatment is recommended for this patient group. In the present study, the rate of patients with an SCD risk of over 6% was significantly higher in the MTWA (+) group, and a positive MTWA significantly correlated with the HCM Risk-SCD ≥6%. A positive MTWA was found to be an independent high-risk predictor for the risk of 5-year SCD. According to these results, the MTWA evaluation in patients with HCM may especially help in predicting the HCM Risk-SCD in patients who are in the high-risk group for HCM.

**Study limitations**

This study is not an epidemiological or randomized study exploring new associations with SCD. A relatively small sample size of HCM patients was included in this study. So, our study is a preliminary study, and it is needed to be reproduced in a larger population. The mean follow-up period of the study was not long enough. A quantitative LGE assessment with CMR was not performed in all patients. Thus, the relationship between the LGE and MTWA could not be assessed clearly. We performed genetic tests in 3 patients and a screening test for Anderson-Fabry disease in 35 patients. Some patients were taking anti-arrhythmic drugs when TWA was measured. We could not perform the test in a drug-free state because of the fear that the patients might develop recurrent ventricular arrhythmias. We did not characterize TWA by the quantitative model.

**Conclusion**

We demonstrated that the presence of MTWA on ambulatory ECG seems to be significantly associated with increasing percentages of the predicted HCM Risk-SCD score in patients with HCM. The MTWA was determined as an independent high-risk indicator for the HCM Risk-SCD. Ventricular arrhythmias, requirement for CPR and ICD therapy, and some ECHO parameters were significantly higher in the HCM patients with positive MTWA.

**Conflict of interest:** None declared.

**Peer-review:** Externally peer-reviewed.

**Authorship contributions:** Concept – S.Ö.; Design – S.Ö.; Supervision – S.Ö.; Fundings – None; Materials – S.Ö., H.P.; Data collection &/or processing – S.Ö., H.P.; Analysis &/or interpretation – H.P.; Literature search – S.Ö.; Writing – S.Ö.; Critical review – H.P.

**References**

1. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borrgreffe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-79.
2. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002; 87: 169-76.
3. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308-20.
4. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al.; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy(HCM Risk-SCD). Eur Heart J 2014; 35: 2010-20.
5. Pusuroglu H, Akoglu O, Erturk M, Bolat I, Tasbulak O, Ornek V, et al. Assessment of relationship between galectin-3 and ambulatory ECG-based microvolt T-wave alternans in sustained systolic-diastolic hypertension patients. Blood Press Monit 2016; 21: 265-70.
6. de Oliveira Antunes M, Samesima N, Pereira Filho HG, Matsumoto AY, Verrier RL, Pastore CA, et al. Exercise-induced quantitative mi-
crovolt T-wave alternans in hypertrophic cardiomyopathy. J Electrocardiol 2017; 50: 184-90.
7. Verrier RL, Klingenhoven T, Malik M, El-Sherif N, Exner DV, Hohnloser SH, et al. Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility--consensus guideline by International Society for Holter and Noninvasive Electrocardiology. J Am Coll Cardiol 2011; 58: 1309-24.
8. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantification of Two- Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67.
9. Devereux RB, Koren MJ, de Simone G, Okin PM, Kligfield P. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J 1993; 14 (Suppl D): 8-15.
10. Nieminen T, Lehtimäki T, Viik J, Lehtinen R, Nikus K, Köbö T, et al. T-wave alternans predicts mortality in a population undergoing a clinically indicated exercise test. Eur Heart J 2007; 19: 2332-7.
11. Hsu SS, Mohib S, Schroeder A, Deger FT. T wave oversensing in implantable cardioverter defibrillators. J Interv Card Electrophysiol 2004; 11: 67-72.
12. Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003; 26: 1887-96.
13. Yalin K, Gölcük E, Teker E, Bilge AK, Adalet K. Is there a role of MMA T wave alternans test for risk assessment in Brugada syndrome? Anatol J Cardiol 2013; 13: 702-4.
14. Schmitt J, Baumann S, Klingenhoven T, Richter S, Duray G, Hohnloser SH, et al. Assessment of microvolt T-wave alternans in high-risk patients with the congenital long-QT syndrome. Ann Noninvasive Electrocardiolog 2009; 14: 340-5.
15. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 1994; 330: 235-41.
16. Momiyama Y, Hartikainen J, Nagayoshi H, Albrecht P, Kautzner J, Saumarez RC, et al. Exercise-induced T-wave alternans as a marker of high risk in patients with hypertrophic cardiomyopathy. Jpn Circ J 1997; 61: 650-6.
17. Montgomery JV, Harris KM, Casey SA, Zenovich AG, Maron BJ. Relation of electrocardiographic phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. Am J Cardiol 2005; 96: 270-5.
18. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 480-7.
19. Özylmaz S, Akgül Ö, Uyarel H, Pusuroğlu H, Karayakalı M, Gül M, et al. Assessment of the association between the presence of fragmented QRS and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy. Anatol J Cardiol 2017; 18: 54-61.
20. Yalin K, Gölcük E, Teker E, Yilmaz R, Dursun M, Bilge AK, et al. No association between scar size and characteristics on T-wave Alternans in post-myocardial infarction patients with relatively preserved ventricular function presented with nonsustained ventricular tachycardia. Anatol J Cardiol 2014; 14: 442-7.
21. Nienaber CA, Gambhir SS, Mody FV, Ratib O, Huang SC, Phelps ME, et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation 1993; 87: 1580-90.
22. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-8.
23. Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, et al. The case for myocardial ischemia in Hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 866-75.
24. Borggreve MM, Lawo T, Butter C, Schmidinger H, Lunati M, Pieske B, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 2008; 29: 1019-28.
25. Özylmaz S, Akgül O, Uyarel H, Pusuroğlu H, Gül M, Satilimisoglu MH, et al. The importance of the neutrophil-to-lymphocyte ratio in patients with hypertrophic cardiomyopathy. Jpn Circ J 2005; 69: 480-7.
26. Maron MS, Zenovich AG, Casey SA, Link MS, Udelson JE, Aeppli DM, et al. Significance and relationship between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. Am J Cardiol 2005; 95: 1329-33.
27. Trivedi A, Knight BP. ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy. Arrhythm Electrophysiolo Rev 2016; 5: 188-96.